Zymeworks Inc.

ZYME

$29.90

-3.70%

N/A-$1.15

Healthcare

Biotechnology

NASDAQ

Active Trading

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed ...

Financial Highlights of ZYME

Profitability trend

Latest / TTM · 6 periods

Gross Margin

87.8%

Net Margin

-404.0%

P/E Ratio

-14.80x

n/a

Debt / Equity

3.34

n/a

Current Ratio

6.32

Dividend Yield

0.0%

Understanding

TTM —

High debt to equity

Interest coverage is weak

Financial highlights

Latest / TTM · 6 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

87.8%

Net Margin

-404.0%

P/E Ratio

-14.80x

Debt / Equity

3.34

Profitability

Profitability table

Metric	2021	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	100.0%	100.0%	-88.1%	100.0%	100.0%	—
Operating MarginOperating income as a percentage of revenue.	-808.2%	31.6%	-181.6%	-179.7%	-87.3%	—
Net MarginNet income as a percentage of revenue.	-794.0%	30.1%	-156.1%	-160.8%	-76.6%	—
EBITDA MarginEBITDA divided by revenue.	-772.4%	34.5%	-158.8%	-142.4%	-64.8%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	-795.9%	32.8%	-156.9%	-152.8%	-75.3%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2021	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	4.01	5.70	7.41	3.40	5.52	—
Quick RatioLiquid assets divided by current liabilities.	4.01	5.70	7.41	3.40	5.52	—
Cash RatioCash and equivalents divided by current liabilities.	2.81	4.19	2.83	0.75	0.97	—
Debt / AssetsDebt as a share of total assets.	8.3%	4.3%	4.6%	4.0%	5.3%	—
Debt / EquityDebt compared with shareholder equity.	0.13	0.06	0.06	0.05	0.07	—

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	1.71x	12.35x	3.90x	1.37x	22.85x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	23.02x	0.00x	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.07x	0.64x	0.13x	0.16x	0.31x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.09x	1.24x	0.19x	0.27x	0.53x	—

Valuation ratios

Valuation ratios table

Metric	2021	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-4.04x	4.12x	-6.04x	-9.04x	-24.38x	—
P/B RatioPrice paid for each dollar of book value.	3.43x	1.04x	1.54x	3.28x	7.39x	—
P/S RatioPrice paid for each dollar of sales.	32.03x	1.24x	9.41x	14.55x	18.72x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-4.15x	3.91x	-5.85x	-9.82x	-57.45x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	0.0%	—

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer